The Question is from neet-botany biotechnology , and it was created by the author Mr. NARESH KUMAR K

Question

A scientist is attempting to develop a novel gene therapy for cystic fibrosis. They are utilizing a modified adeno-associated virus (AAV) vector to deliver the functional CFTR gene.  However, pre-clinical trials show limited efficacy due to pre-existing neutralizing antibodies against the AAV capsid in a significant portion of the target population. Which of the following strategies would be MOST effective in overcoming this limitation?

Mr. NARESH KUMAR K · Accepted Answer

## CORE INFORMATION
✓ **Answer**: C
## CONCEPT FRAMEWORK
 **Primary Concept**: Gene therapy challenges and overcoming limitations
 **Related Topics**: Adeno-associated virus (AAV) vectors, neutralizing antibodies, immunogenicity, gene delivery systems
 **Prerequisites**: Understanding of gene therapy principles, immune response to viral vectors
## SOLUTION PATHWAY
**Given Information**:
  * Limited efficacy of AAV-based gene therapy for cystic fibrosis due to pre-existing neutralizing antibodies.
  * Neutralizing antibodies target the AAV capsid.
**Method & Steps**:
 1. Analyze the problem: The primary obstacle is the pre-existing immune response neutralizing the AAV vector before it can deliver the CFTR gene. 
  Reasoning: The body's immune system recognizes and destroys the AAV vector before it can reach the target cells.
  Formula/Rule: None directly applicable, this is a qualitative analysis problem.
 2. Evaluate the options:
  Working: Let's examine each option's effectiveness in addressing the pre-existing antibodies:
  A. Increasing the dosage might overwhelm the immune response in some individuals but is not a targeted solution and could lead to increased toxicity.
  B. Immunosuppressants broadly suppress the immune system, increasing the risk of infection and other complications. This is a risky approach.
  C. Altering the AAV capsid surface epitopes directly targets the problem by making the vector less recognizable to the pre-existing antibodies. This is a precise and targeted strategy.
  D. Switching vectors changes the problem, but doesn't solve the underlying issue of pre-existing immunity.  The patient might have pre-existing immunity to the new vector as well.
 3. Choose the best strategy: Engineering AAV capsids is the most effective and targeted approach to overcome pre-existing immunity.
  Result: Option C
  Verification: Option C directly addresses the root cause of the problem – the neutralizing antibodies targeting the AAV capsid – without introducing significant additional risks.
 ## OPTION ANALYSIS
A :x: Increasing the dosage is unlikely to overcome the problem of pre-existing neutralizing antibodies and could lead to increased toxicity.
B :x: Immunosuppression is a high-risk strategy with potential for severe side effects and is not a targeted approach.
C ✓: Engineering altered AAV capsids is a precise and effective strategy to evade the immune response and deliver the functional CFTR gene.
D :x: Switching to a different vector doesn't address the underlying issue of pre-existing neutralizing antibodies and might lead to similar problems with the new vector.
 ## LEARNING AIDS
 **Common Mistakes**:
  1. Choosing immunosuppression: This is a high-risk approach with many side effects.
  2. Focusing solely on increasing the dose: This doesn't address the root cause of the problem.
 **Quick Tips**:
  1. Identify the core problem: Pre-existing antibodies targeting the AAV capsid.
  2. Choose the most targeted solution: Engineering the AAV capsid to evade the immune response.

Mr. NARESH KUMAR K · Answer

Increasing the dosage of the AAV vector.

Mr. NARESH KUMAR K · Answer

Administering immunosuppressants prior to gene therapy.

Mr. NARESH KUMAR K · Answer

The correct Option is "Engineering AAV capsids with altered surface epitopes to evade pre-existing immunity."

Mr. NARESH KUMAR K · Answer

Switching to a lentiviral vector delivery system.

NEET Botany Biotechnology and Its Applications MCQs

Select Topic

Question Tags

Question Tags

Question Tags

Question Tags

Question Tags

Question Tags

Question Tags

Question Tags

Question Tags

Question Tags

NEET Subjects

Our Bots

Company